Connect with us

Business

Third member of prestigious FDA panel resigns over approval of Biogen’s Alzheimer’s drug – CNBC

A third member of a key FDA panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug,…

Published

on

Article feature image
ADVERTISEMENT

A third member of a key Food and Drug Administration advisory panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, CNBC has learned.
Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
‘Electrification is a given,’ says Harley-Davidson CEO Jochen Zeitz, but HOG’s success in EVs is less certain – CNBC
Article feature image
Heading back to work after retiring? That cash may impact the rest of your financial life – CNBC
Article feature image
Bitcoin price can hit $450K in 2021, $135K is ‘worst-case scenario’ — PlanB – Cointelegraph